Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 19, 2026

Maxim Power Corp. Announces 2025 Fourth Quarter Financial and Operating Results

View original at globenewswire.com
Maxim Power Corp. Announces 2025 Fourth Quarter Financial and Operating Results CALGARY, Alberta, March 19, 2026 (GLOBE NEWSWIRE) -- Maxim Power Corp…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Corporation continues to advance all aspects of project development for Prairie Lights and anticipates total project spending during 2026 of up to $60 million

    60% confidence

  • Net income and Adjusted EBITDA decreased in 2025 primarily due to lower generation volumes, as a result of a planned maintenance outage in the fourth quarter of 2025, and a lower realized average power price

    60% confidence

  • As of the date hereof, the precise amount and timing of any further compensation related to the Claim, if any, cannot be determined

    60% confidence

  • The collective amount of the insurance policies for the remaining third parties involved in the Claim is equivalent to the amount paid out as part of the settlement announced on November 24, 2025

    60% confidence

  • The amendment to Prairie Lights regulatory permits based on the 7HA.02 gas turbine is anticipated to be routine in nature

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Maxim Power Corp. Announces 2025 Fourth Quarter Financial and Operating Results — Source | Via News | ViaNews Market